Cited 32 times in
IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.